Protara Therapeutics (TARA)
(Delayed Data from NSDQ)
$3.11 USD
-0.04 (-1.27%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $3.12 +0.01 (0.32%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TARA 3.11 -0.04(-1.27%)
Will TARA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TARA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARA
Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
TARA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TARA
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ...
Catalio Capital Management Raises Over $400M to Invest in Innovative Healthcare Companies in ...
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ...
Protara Therapeutics (TARA) Added to Russell 3000 Index
Protara Therapeutics added to the Russell 3000 index